Grover Disease Associated With Chemotherapy: Review of Potential Pathophysiology, Current Treatments, and Future Directions.
CONCLUSIONS: Chemotherapy-associated Grover disease is an uncommon complication of cancer treatment. While most cases of chemotherapy-associated Grover disease can be treated with topical steroids and topical emollients, certain cases require a more specialized approach. This could include adjuvant adjuvant therapies, or novel treatments that are directly related to the mechanism of action of the chemotherapy involved. J Drugs Dermatol. 2020;19(11):1056-1064. doi:10.36849/JDD.2020.5648. PMID: 33196735 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Revisiting Handwashing - As It Is Absolutely Essential.
Authors: Litchman GL, Marson JW, Bhatia N, Berman B Abstract As the coronavirus pandemic continues into the second half of 2020, states across the US remain steadfast in their search to determine the safest methods of returning to normalcy. Without a readily available, effective COVID-19 vaccine, and as the numbers of infected individuals continues to climb, the best practices to ensure public safety are rooted in good personal hygiene and prevention of transmission of the novel coronavirus SARS-CoV-2. To that end, in addition to properly wearing adequate facial covering, individuals should properly wash their hand...
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Red Deer Umbilical Cord-Derived Stem Cell Conditioned Media Combined With Ablative Resurfacing of the Face.
CONCLUSION: Red deer umbilical cord-derived stem cell conditioned media (USCCM) is well tolerated, safe and efficacious for use pre- and post- facial laser resurfacing.J Drugs Dermatol. 2020;19(11): 1044-1048 doi:10.36849/JDD.2020.5246. PMID: 33196737 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Rapid Evolution of a Squamous Cell Carcinoma In Situ to Locally Invasive With Perineural Involvement.
We present a case of rapidly progressing squamous cell carcinoma in situ (SCCis) with progression to aggressive SCC. An elderly gentleman with multiple medical comorbidities presented with a left zygomatic tumor initially diagnosed as SCCis with adnexal extension on histology. After a period of approximately 10 weeks, the patient underwent Mohs micrographic surgery (MMS) with evidence that the tumor was now consistent with a well-differentiated SCC, with perineural involvement. MMS was stopped after two stages and the patient was sent to head and neck surgical oncology for further evaluation and management. It has been rep...
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Prevention of Scarring With Intraoperative Erbium: YAG Laser Treatment.
CONCLUSIONS: This study demonstrates that a 2,940-nm erbium:YAG laser treatment, performed immediately after surgery, can improve the appearance of a surgical scar. J Drugs Dermatol. 2020;19(11): 1040-1043. doi:10.36849/JDD.2020.5244. PMID: 33196739 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Remission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline.
Authors: Gul MI, Singam V, Hanson C, Neill BC, Aires DJ, Rajpara AN PMID: 33196740 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Geographic Variations in Biologic Therapy and Disease Characteristics: A Pilot-Study in the Corrona Psoriasis Registry.
Authors: Enos CW, O'Connell KA, Harrison RW, McLean RR, Dude B, Van Voorhees AS PMID: 33196741 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Potential for Teledermatology in Managing and Diagnosing Patients With Cutaneous Lymphomas.
Authors: Beer J, Hadeler E, Nouri K PMID: 33196742 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Ablative Fractional Resurfacing for Chronic Wounds from Traumatic Scarring: A Case Report and Literature Review.
We present a case of scarring with non-healing ulceration refractory to wound care, debridement and hydrotherapy successfully healed in four sessions with AFR using a 2940 nm Er:YAG laser. We review the literature on AFR for wound healing including potential mechanisms. AFR can be considered for non-healing ulcers in areas of scarring, once malignancy and infection are ruled out, and has the potential to provide relief for these suffering patients.J Drugs Dermatol. 2020;19(11): doi:10.36849/JDD.2020.5444. PMID: 33196743 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Influence of Different Treatment Combinations on Skin Laxity and Dimpling.
CONCLUSION: This study provides evidence for the effectiveness of combination therapies for the improvement of skin surface irregularities on the buttocks and thighs. J Drugs Dermatol. 2020;19(11): 1030-1038. doi:10.36849/JDD.2020.5117. PMID: 33196744 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

ARTICLE: A Novel Antibiotic Just for Acne.
Authors: Kircik LH Abstract Dermatologists consistently rank as the most frequent prescribers of systemic antibiotics, and one of the most common diagnoses for which we recommend these agents is acne vulgaris. Up to three quarters of the antibiotics that dermatologists prescribe are in the tetracycline class.1 Even though dermatology as a specialty is well-known for off-label prescribing, it may be surprising to note that no systemic antibiotic had been FDA approved solely for treatment of acne—until recently. PMID: 33196745 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

ARTICLE: Oral Tetracyclines and Acne: A Systematic Review for Dermatologists.
Authors: Armstrong AW, Hekmatjah J, Kircik LH Abstract Oral tetracyclines are the most widely prescribed systemic antibiotic for acne. Synthesis of efficacy and safety of traditional and novel oral tetracyclines is highly informative to clinical practice. We conducted a systematic search of PubMed to identify large interventional and observational studies utilizing oral tetracyclines as an acne treatment. We identified 13 articles meeting inclusion for this review, which represented 226,019 pediatric and adult acne patients. Oral tetracyclines that were included in this systematic review were sarecycline (a novel n...
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.
CONCLUSIONS: Participants treated with tazarotene 0.045% lotion had significant quality-of-life improvements. Clinician-rated symptom severity appeared to have a smaller effect on Acne-QoL outcomes than participants’ own assessments of quality of life. J Drugs Dermatol. 2020;19(11): doi:10.36849/JDD.2020.5457. PMID: 33196747 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Choosing the Right Partner: Complementing Prescription Acne Medication With Over-the-Counter Cleansers and Moisturizers.
CONCLUSION: Informing clinicians about skin barrier dysfunction in acne and the benefits of adjunctive skincare may help them to choose the right product(s) to complement prescription therapy. J Drugs Dermatol. 2020;19(11): doi:10.36849/JDD.2020.5536. PMID: 33196748 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Variables Affecting Delivery of Glycopyrronium Tosylate Through Human Skin In Vitro.
CONCLUSION: These in vitro skin penetration studies showed that skin thickness, exposure time, and occlusion substantially influenced GT delivery, potentially impacting clinical trial design. J Drugs Dermatol. 2020;19(11): doi:10.36849/JDD.2020.5062. PMID: 33196749 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Therapies for Psoriasis: Clinical and Economic Comparisons.
Authors: Marchetti A, Bhutani T, Lockshin B, Siegel DM, Behringer F Abstract BACKGROUND: Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new devel- opment in the field. With the recent availability of a novel accessory (Multi Micro DoseTM [MMD®] tip) for the 308nm excimer laser (XTRAC®, Strata Skin Sciences, Horsham, PA), which can determine and deliver an optimal therapeutic dose (OTDTM) of ultraviolet-B light in an improved protocol, the need for comparative health-economic assessment recurs. To this end, a comprehensive evaluation of treatm...
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Scleroderma in the Setting of Long-term Intermittent Phentermine Use.
Authors: Beer J, Maderal A PMID: 33196751 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Clinical Trial Evaluating the Long-Term Efficacy of Microfocused Ultrasound With Visualization for D écolleté Rejuvenation.
The objective of the following study was to assess the long-term effects of MFU-V for the treating chest wrinkles. Each subject was treated with 4-4.5 mm, 7-3.0 mm, and 10-1.5 mm transducers. Subjects were subsequently evaluated on post-treatment days 6, 12, 180, and 360. Digital images were obtained of the décolleté area of each subject prior to treatment and at each follow-up evaluation. Wrinkle severity was assessed using the validated Merz Décolletage Wrinkle Scales at each follow-up visit and Subject Satisfaction Questionnaires were completed on post-treatment days 180 and 360. Enrolle...
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Association of Professors of Dermatology Program Directors Task Force and Residency Program Transparency Work Group Guidelines on Residency Program Transparency.
Authors: Rosmarin D, Friedman AJ, Burkemper NM, Nord KM, Murina AT, Huang JT PMID: 33196753 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Sequential Treatment of Actinic Keratosis and Photoaging by Daylight PDT and Injectable NASHA Gel as Skin Booster.
DISCUSSION: The combination of two minimally invasive treatments showed to be effective giving the almost complete resolution of AK and a clear improvement of skin texture, with noticeable reduction of the clinical signs of skin photoaging, meeting patient’s expectations. J Drugs Dermatol. 2020;19(11): doi:10.36849/JDD.2020.2229. PMID: 33196754 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Fractional CO2 Laser Treatment for Vulval Skin and Objective Quantifiable Effect on Vaginal pH.
Authors: Alexiades M PMID: 33196755 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Wound Healing Treatments After Ablative Laser Skin Resurfacing: A Review.
Authors: Leight-Dunn H, Chima M, Hoss E Abstract Laser resurfacing has progressed since the 1980s to treat a variety of medical and aesthetic indications with ever-evolving safety parameters. While laser technology has evolved to provide a more favorable safety profile and decrease wound healing time, advances in post-procedure healing agents have also helped to mitigate adverse effects, such as persistent erythema, dyspigmentation, acneiform eruptions, dermatitis, infections, and scarring. We reviewed the evidence of growth factors, stem cells, silicone and silicone polymers, botanical based treatments, fatty acid...
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

At-Home Transvaginal Device Following Fractional Carbon Dioxide Laser Treatment for Genitourinary Syndrome of Menopause.
CONCLUSIONS: At-home transvaginal red and near infrared light therapy commencing at 12 months post-FxCO2 vulvovaginal treatment in a post-menopausal population maintained statistically significant improvements in vulvovaginal and SUI symptoms over the additional12-month period (2 years post-laser); however, a gradual return of symptoms suggests that laser re-treatment or combination withhormone therapy may be necessary to maintain optimal outcomes.J Drugs Dermatol. 2020;19(11):1076-1079. doi:10.36849/JDD.2020.1012. PMID: 33196757 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
CONCLUSION: Tirbanibulin ointment 1% was well tolerated and active in AK reduction. Based on activity, the 5-day regimen was selected for Phase 3 development. Clinicaltrials.gov: NCT02337205; NCT02838628 J Drugs Dermatol. 2020;19(11):1093-1100. doi:10.36849/JDD.2020.5576THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN. NO PURCHASE NECESSARY. PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS. PMID: 33196758 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Exchanging Dermatoscopes for Stethoscopes: Has the COVID-19 Pandemic Highlighted Gaps in US Dermatology Residency Training?
Authors: Shaw KS, Karagounis TK, Yin L, Svigos K, Gibbon GT, Betensky RA, Lo Sicco KI PMID: 33026742 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Complication of Soft Tissue Fillers: Prevention and Management Review.
Authors: Galadari H, Krompouzos G, Kassir M, Gupta M, Wollina U, Katsambas A, Lotti T, Jafferany M, Navarini AA, Vasconcelos Berg R, Grabbe S, Goldust M Abstract The use of dermal fillers has increased manifold over the past decade, which has been attributed to the ever-increasing need of the population for being young. Fillers have become quite popular both among patients and treating physicians due to their quick and quite predictable results. Filler injection is a safe procedure in the hands of an experienced provider using appropriate technique. Nevertheless, various adverse effects to fillers have been reporte...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Reconstruction of Cutaneous Defects of the Ear Using the Post-Auricular Reservoir: A Systematic Review.
CONCLUSIONS: A post-auricular approach for repair of auricular defects can provide a reasonable option for single and multi-staged closure to create an excellent aesthetic outcome while hiding the donor site. More prospective data is required to determine the overall best approach. J Drugs Dermatol. 2020;19(9):883-888. doi:10.36849/JDD.2020.5106. PMID: 33026744 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Impact of COVID-19 on the Faces of Frontline Healthcare Workers.
The objective of this article is to provide effective and straightforward recommendations to those health care providers using facial masks in order to prevent skin-related complications. J Drugs Dermatol. 2020;19(9):858-864. doi:10.36849/JDD.2020.5259. PMID: 33026745 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Systemic Medications of Dermatological Importance in COVID-19.
Authors: Schwartz RA, Sharma A, Szepietowski JC, Sandhu S, Goldust M Abstract Early December 2019 witnessed an international outbreak of a novel coronavirus (COVID 19) designated severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). Since then, a number of therapeutic molecules have been explored to have potential efficacy against the SARS-Cov-2 per se or its sequelae. There are no Food and Drug Administration specific therapies approved so far; however, numerous drugs based on varying levels of evidence, in vitro studies and compassionate drug trials are being established as therapeutic agents, especially ...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

The Impact of Pharmacy Benefit Managers on Drug Pricing.
Authors: Patel DJ, Bhatia N, Kaufmann MD PMID: 33026747 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Safety and Effectiveness of Hyaluronic Acid Fillers With Lidocaine for Full-Face Treatment in Asian Patients.
CONCLUSION: Full-face treatments with the study products resulted in long-term aesthetic improvement, perceived by both subjects and investigators. Subject satisfaction was high and maintained over 24 months with one re-treatment. Repeated treatment of several facial indications showed a satisfactory safety profile. J Drugs Dermatol. 2020;19(9):836-842. doi:10.36849/JDD.2020.5374. PMID: 33026748 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
CONCLUSIONS: In the treatment of moderate plaque psoriasis, Cal/BD foam plus apremilast provided more benefits than with apremilast alone. These improvements appeared to be lost when Cal/BD foam was withdrawn but recovered when Cal/BD foam was reinitiated. J Drugs Dermatol. 2020;19(9):874-880. doi:10.36849/JDD.2020.5020. PMID: 33026749 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Cutaneous Manifestations of EGFR-Inhibitors in African Americans and Treatment Considerations.
Authors: Geisler AN, Noor SJ Abstract Epidermal growth factor (EGFR)-inhibitors have emerged as the primary therapy in advanced solid tumor malignancies because of improvement in survival with overall favorable side effect profile. However, 50–90% of patients treated with EGFR-inhibitors develop a follicular or acneiform rash, which can be symptomatic and source of psychosocial distress, negatively impacting quality of life. As this acneiform rash is a well-recognized cutaneous toxicity of EGFR-inhibitors, a treatment algorithm has been proposed for management based on severity. However, treatment options...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Human Pharmacokinetics and Safety of Subcutaneous Collagenase Clostridium Histolyticum in Women.
CONCLUSIONS: In human studies, no quantifiable circulating CCH levels were observed after a single subcutaneous dose of CCH up to 3.36 mg. Preclinical data indicated that repeat IV dosing (QOD; 8 doses) at ≥43× proposed human dose on a mg/kg basis for CCH was generally well tolerated.J Drugs Dermatol. 2020;19(9):852-856. doi:10.36849/JDD.2020.5048THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN. NO PURCHASE NECESSARY. PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS. PMID: 33026751 [PubMed - as supplied by publisher] (Sour...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Efficacy and Safety of Intense Pulsed Light With a KTP/PDLlike Filter for the Treatment of Facial Telangiectasias.
CONCLUSIONS: The use of a novel IPL narrowband KTP/PDL-like filter can significantly improve facial and non-facial telangiectasias with minimal downtime. J Drugs Dermatol. 2020;19(9):844-850. doi:10.36849/JDD.2020.4834. PMID: 33026752 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
CONCLUSION: Efinaconazole was safe and efficacious in pediatric participants with mild-to-severe onychomycosis, with improved mycologic cure and complete cure rates compared with adults from two 52-week studies. J Drugs Dermatol. 2020;19(9):867-872. doi:10.36849/JDD.2020.5401. PMID: 33026753 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Biological Effects of Hyaluronic Acid-Based Dermal Fillers and Laser Therapy on Human Skin Models.
Authors: Huth L, Marquardt Y, Heise R, Fietkau K, Baron JM, Huth S Abstract Injection of dermal fillers is one of the most frequently performed aesthetic procedures. The aim of the present study was to investigate the biological effects of different stabilized hyaluronan (HA) and poly-l-lactic acid fillers with and without subsequent additional fractional laser co-treatment on skin morphology and gene expression. Intradermal injection resulted in a significant enhancement of epidermal thickness detected by histological analysis. Combining HA fillers with ablative fractional CO2- or Er:YAG laser irradiation enhanced...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
CONCLUSION: HQ-free, retinol-free CTB and HQ 4% both are effective and well-tolerated in the treatment of moderate facial melasma in FST III–VI. J Drugs Dermatol. 2020;19(9):822-827. doi:10.36849/JDD.2020.5353. PMID: 33026755 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience.
CONCLUSIONS: Lanadelumab is an effective but expensive long-term prophylaxis for HAE patients. A favorable side-effect profile has been shown. J Drugs Dermatol. 2020;19(10):978-983. doi:10.36849/JDD.2020.5269. PMID: 33026762 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Hyaluronidase in Dermatology: Uses Beyond Hyaluronic Acid Fillers.
We describe the varied uses of hyaluronidase in dermatology and the underlying evidence base for its dermatological indications. This includes its uses in enhancing drug delivery (for local anesthesia, keloid and hypertrophic scars, and for Kaposi’s sarcoma), in the treatment of disorders associated with mucin deposition (myxedema, scleroderma, scleredema, and cutis verticis gyrata) and its potential uses in surgery (as a pre-operative adjuvant in dermatofibrosarcoma protuberans, for periorbital edema, and for hematomas). In select circumstances, hyaluronidase might be more efficacious than more established treat...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Clinical Relevance of Skin Pain in Atopic Dermatitis.
Authors: Ständer S, Simpson EL, Guttman-Yassky E, Thyssen JP, Kabashima K, Ball SG, Rueda MJ, DeLozier AM, Silverberg JI Abstract Skin pain is increasingly recognized as an impactful symptom in atopic dermatitis (AD) because of its association with patient discomfort, disease burden, and reduced quality of life. Although the nature of skin pain in AD has not been systematically studied and is therefore not well understood, patients report soreness, discomfort, and tenderness that may reflect peripheral and central pain sensitization. The high prevalence of skin pain suggests that it is not adequately addressed...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Development and Evaluation of an Atopic Dermatitis Care Plan for Providers.
Authors: Utley C, Gold MH, Hall M Abstract Background/Significance of problem: Atopic Dermatitis (AD) is a common, chronic, inflammatory dermatosis and skin disease that follows a relapsing pattern and requires a dynamic stepwise approach to management.Providers feel comfortable treating chronic disease states with a guided tool or care plan in many chronic diseases.Care plans used in many chronic diseases such as asthma, diabetes, and COPD have demonstrated effectiveness in disease and healthcare provider management.There is an unmet need for a universal AD care plan for providers. Clinical question/project purpos...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Hydrogen Peroxide Topical Solution, 45% for Common Warts: Phase 2 Efficacy and Safety Trial Results.
CONCLUSION: These findings support the efficacy and safety of HP45 for the treatment of common warts in patients ≥8 years of age. J Drugs Dermatol. 2020;19(10):969-976. doi:10.36849/JDD.2020.5054. PMID: 33026766 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
Authors: Uppal SK, Chat VS, Kearns DG, Wu JJ Abstract Mild to moderate atopic dermatitis (AD) occurs frequently in children and adults and is usually managed through the use of pharmacologic treatments, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), and good skin care practices. As chronic TCS or TCI can lead to the development of adverse effects, there is a need for safe, alternative treatments for patients with resistant AD. A systemic literature review was performed to examine the safety and efficacy of topical agents currently in phase II and phase III clinical trials for AD. O...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

ARTICLE: Colloidal Oatmeal Part I: History, Basic Science, Mechanism of Action, and Clinical Efficacy in the Treatment of Atopic Dermatitis.
Authors: Allais B, Friedman A Abstract Colloidal oatmeal has a long-standing history in the treatment of dermatologic disease. It is composed of various phytochemicals, which contribute to its wide-ranging function and clinical use. It has various mechanisms of action including direct anti-inflammatory, anti-pruritic, anti-oxidant, anti-fungal, pre-biotic, barrier repair properties, and beneficial effects on skin pH. These have been shown to be of particular benefit in the treatment of atopic dermatitis. In Part 1 of this two-part series, we will explore the history of colloidal oatmeal, basic science, mechanism of...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

ARTICLE: Colloidal Oatmeal Part II: Atopic Dermatitis in Special Populations and Clinical Efficacy and Tolerance Beyond Eczema.
Authors: Allais B, Friedman A Abstract Colloidal oatmeal has a diverse array of applications, clinical benefits, and uses beyond atopic dermatitis. First and foremost, it has been shown to be of benefit in the treatment of atopic dermatitis in skin of color. It has also been shown to be of benefit in the treatment of hand dermatitis, xerosis, psoriasis, skin manifestations of diabetes, and in the treatment of cutaneous adverse effects associated with oncologic therapies. In Part II of this 2-part series, we examine the efficacy, safety, and expansive clinical applications of colloidal oatmeal. J Drugs Dermatol. 202...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study.
CONCLUSIONS: In patients with AD, quality of life was most affected in patients with lesions in visible areas, including head/neck, hands/fingers, and upper extremities, with statistically significant associations for a number of DLQI domains. Physicians should be aware of the burden of AD lesions on QoL and consider having conversations with patients to better understand the impact of these lesions. Prior presentation: 28th Annual European Academy of Dermatology and Venereology Congress; 9–13 October 2019, Madrid, Spain. Poster number P0233.J Drugs Dermatol. 2020;19(10): 943-948. doi:10.36849/JDD.2020.5422. ...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
CONCLUSIONS: These results demonstrate a dose effect of at least 6 months duration with higher doses in the majority of GFL subjects. All doses were well tolerated and safety was consistent with the known safety profile of 20U INCO for GFL. J Drugs Dermatol. 2020;19(10):985-991. doi:10.36849/JDD.2020.5454. PMID: 33026771 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report.
We present the case of a 58-year-old Black male with moderate psoriasis who was treated for 8 weeks with a fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion during a phase 3 study (NCT02462070). HP/TAZ was efficacious in this patient, whose Investigator’s Global Assessment score decreased from 3 (moderate) at baseline to 1 (almost clear) within 4 weeks, with maintenance of “almost clear” through week 12 (4 weeks posttreatment). Affected body surface area decreased by 50% and quality of life greatly improved from baseline to week 8. The patient experienced dyspigm...
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Persistent Agminated CD30+ Lymphoproliferative Disorder.
Authors: Beer J, Bittar PG, Bittar JM, Elenitsas R, Haun P PMID: 33026773 [PubMed - as supplied by publisher] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research